Group 1 - Kenvue Inc. (NYSE:KVUE) is considered one of the most oversold large-cap stocks in 2025, with Barclays lowering its price target from $20 to $17 while maintaining an Equal Weight rating [1] - The company operates in the consumer health sector through three segments: Skin Health and Beauty, Self Care, and Essential Health [2] - The Skin Health and Beauty segment includes various product categories such as hair care, body care, and face care, with a global presence in over 165 countries [3] Group 2 - The firm has adjusted its growth models to reflect "muted and decelerating" growth in certain areas of the personal care domain since the Q2 reports [2] - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to Kenvue [4]